mitochondrial bioenergetics

Glibenclamide (Glyburide) is an antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.

3-hydroxy Palmitic acid is a form of the 16:0 lipid palmitic acid . The lipid A part of lipopolysaccharides contain various 3-hydroxy fatty acids, making oxylipins such as 3-hydroxy palmitic acid useful as chemical markers of endotoxins. In R. solanacearum, 3-hydroxy palmitic acid is converted by an S-adenosyl methionine-dependent methyltransferase to 3-hydroxy palmitic acid methyl ester, which acts as a quorum sensing signal molecule for post-transcriptional modulation of genes involved in virulence. Long-chain 3-hydroxy fatty acids, such as 3-hydroxy palmitic acid, are also known to accumulate during long-chain 3-hydroxy-acyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies. Such accumulation induces oxidative stress, leading to mitochondrial bioenergetics deregulation and eventual multi-organ dysfunction.

PDK-IN-2 (Compound 1F), with an IC50 of 68 nM, is a potent PDK inhibitor that downregulates the expression of PDK1 and PDK4 in cells. It promotes mitochondrial bioenergetics, reduces glycolytic activity, and triggers apoptosis via the mitochondrial pathway. Additionally, PDK-IN-2 has been shown to impede tumor growth in a 4T1 syngeneic mouse model [1].

Glyburide-d3 is the deuterated form of Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor, utilized in the research of diabetes and obesity. It inhibits P-glycoprotein, directly binds to and blocks the SUR1 subunit of KATP, and suppresses the cystic fibrosis transmembrane conductance regulator (CFTR). Additionally, Glibenclamide interferes with mitochondrial bioenergetics by inducing membrane ion permeability and can induce autophagy.

Glyburide-d11 is a deuterated form of Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor used in the study of diabetes and obesity. It inhibits P-glycoprotein and directly binds to block the SUR1 subunit of KATP, also inhibiting cystic fibrosis transmembrane conductance regulator (CFTR). Glibenclamide interferes with mitochondrial bioenergetics by inducing membrane ion permeability and can induce autophagy.

Glibenclamide (Standard) is the analytical reference standard of Glibenclamide intended for research and quantitative applications, and as an orally active ATP-sensitive potassium channel inhibitor, Glibenclamide directly binds SUR1 subunits of KATP channels, inhibits P-glycoprotein and CFTR, alters mitochondrial membrane ion permeability, induces autophagy, and supports research in diabetes, obesity, and cellular bioenergetics.

Bid BH3 peptide, a small peptide derived from the Bid protein, binds to and activates the pro-apoptotic proteins Bax and Bak, leading to mitochondrial outer membrane permeabilization (MOMP) and cell apoptosis (apoptosis). This peptide is utilized in research on mitochondrial bioenergetics.